[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"malignant-skin-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:malignant-skin-neoplasm":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100568010","digital-remote-monitoring-of-immune-checkpoint-inhibitor-therapy-induced-toxicity-using-the-vigilant-app-100568010",false,"NCT06675643","Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant App","Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity: A Feasibility Study of the Vigilant App (Vigilant-2)","Inclusion Criteria:\n\n* Any skin cancer\u002Fmelanoma patient starting dual \\[ipilimumab\u002Fnivolumab (IPI\u002FNIVO)\\] immune checkpoint inhibitor (ICI) therapy\n\nExclusion Criteria:\n\n* Does not meet inclusion criteria","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","This study is being done to better understand patient experiences with using a mobile application, known as Vigilant, to monitor symptoms as outpatients and to gather preliminary data on the potential clinical benefit to remote monitoring of adverse events.",[24,25],"Malignant Skin Neoplasm","Melanoma","RECRUITING","2026-02-06",{"date":29,"type":30},"2026-02-10","ACTUAL",{"date":32,"type":30},"2024-10-14",{"date":34,"type":20},"2027-03-15",{"name":36,"class":37},"Mayo Clinic","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":5},"100609328","optical-imaging-scans-for-the-diagnosis-of-skin-cancer-in-patients-with-lesions-100609328","NCT07213154","Optical Imaging Scans for the Diagnosis of Skin Cancer in Patients With Lesions","Assessment of Novel Label-free Optical Imaging Technology for the Evaluation of Skin Lesions","Inclusion Criteria:\n\n* Male or Female\n* Candidate with skin lesions\n* Signed study-specific informed consent prior to study entry\n* ≥ 18 years old\n\nExclusion Criteria:\n\n* Prior surgery or radiotherapy to the area to be treated",{"count":47,"type":20},10,"INTERVENTIONAL",[50],"NA","This clinical trial studies how well an optical imaging scan called quantitative oblique back-illumination microscopy (qOBM) helps in diagnosing skin cancer in patients with skin lesions. qOBM is a non-invasive procedure that uses red light for illumination, and may work better than no imaging procedures in aiding doctors in diagnosing skin lesions.",[24,53,54],"Skin Disorder","Skin Neoplasm","2025-12-11",{"date":57,"type":30},"2025-12-16",{"date":59,"type":30},"2025-10-15",{"date":61,"type":20},"2027-09-17",{"name":63,"class":37},"Emory University"]